Propafenone: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Propafenone}} | |||
{{CMG}}; {{AE}} {{SS}} | |||
'''''For patient information about Propafenone, click [[Propafenone (patient information)|here]].''''' | |||
{{SB}} RYTHMOL<sup>®</sup>;RYTHMOL SR<sup>®</sup>;generic | |||
==Overview== | |||
==Category== | |||
[[Category:Antiarrhythmic agents]];[[Ketones]];[[Phenol ethers]];[[Alcohols]];[[Amines]];[[Sodium channel blockers]];[[Cardiovascular Drugs]] | |||
==FDA Package Insert== | |||
====RYTHMOL (propafenone hydrochloride) tablet, film coated ==== | |||
''' [[RYTHMOL indications and usage|Indications and Usage]]''' | |||
'''| [[RYTHMOL dosage and administration|Dosage and Administration]]''' | |||
'''| [[RYTHMOL dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[RYTHMOL contraindications|Contraindications]]''' | |||
'''| [[RYTHMOL warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[RYTHMOL adverse reactions|Adverse Reactions]]''' | |||
'''| [[RYTHMOL drug interactions|Drug Interactions]]''' | |||
'''| [[RYTHMOL use in specific populations|Use in Specific Populations]]''' | |||
'''| [[RYTHMOL overdosage|Overdosage]]''' | |||
'''| [[RYTHMOL description|Description]]''' | |||
'''| [[RYTHMOL clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[RYTHMOL nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[RYTHMOL clinical studies|Clinical Studies]]''' | |||
'''| [[RYTHMOL how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[RYTHMOL patient counseling information|Patient Counseling Information]]''' | |||
'''| [[RYTHMOL labels and packages|Labels and Packages]]''' | |||
<font color="#F8F8FF"> | |||
{| style="border: 3px solid #696969;" align="center" | |||
| style="background: #000000; border: 0px; padding: 0 5px; width: 800px;" | | |||
<center> | |||
'''BOXED WARNING''' | |||
</center> | |||
<center> | |||
''See full prescribing information for complete boxed warning.'' | |||
</center> | |||
<b> | |||
WARNING: MORTALITY | |||
See full prescribing information for complete boxed warning. | |||
* | |||
An increased rate of death or reversed cardiac arrest rate was seen in subjects treated with encainide or flecainide (Class IC antiarrhythmics) compared with that seen in subjects assigned to placebo. At present it is prudent to consider any IC antiarrhythmic to have a significant risk of provoking proarrhythmic events in patients with structural heart disease. | |||
* | |||
Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with non-life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs. | |||
</b> | |||
|} | |||
</font> | |||
====RYTHMOL SR (propafenone hydrochloride) capsule, extended release==== | |||
''' [[RYTHMOL SR indications and usage|Indications and Usage]]''' | |||
'''| [[RYTHMOL SR dosage and administration|Dosage and Administration]]''' | |||
'''| [[RYTHMOL SR dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[RYTHMOL SR contraindications|Contraindications]]''' | |||
'''| [[RYTHMOL SR warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[RYTHMOL SR adverse reactions|Adverse Reactions]]''' | |||
'''| [[RYTHMOL SR drug interactions|Drug Interactions]]''' | |||
'''| [[RYTHMOL SR use in specific populations|Use in Specific Populations]]''' | |||
'''| [[RYTHMOL SR overdosage|Overdosage]]''' | |||
'''| [[RYTHMOL SR description|Description]]''' | |||
'''| [[RYTHMOL SR clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[RYTHMOL SR nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[RYTHMOL SR clinical studies|Clinical Studies]]''' | |||
'''| [[RYTHMOL SR how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[RYTHMOL SR patient counseling information|Patient Counseling Information]]''' | |||
'''| [[RYTHMOL SR labels and packages|Labels and Packages]]''' | |||
<font color="#F8F8FF"> | |||
{| style="border: 3px solid #696969;" align="center" | |||
| style="background: #000000; border: 0px; padding: 0 5px; width: 800px;" | | |||
<center> | |||
'''BOXED WARNING''' | |||
</center> | |||
<center> | |||
''See full prescribing information for complete boxed warning.'' | |||
</center> | |||
<b> | |||
WARNING: MORTALITY | |||
See full prescribing information for complete boxed warning. | |||
*An increased rate of death or reversed cardiac arrest rate was seen in subjects treated with encainide or flecainide (Class IC antiarrhythmics) compared with that seen in subjects assigned to placebo. At present it is prudent to consider any IC antiarrhythmic to have a significant risk of provoking proarrhythmic events in patients with structural heart disease. | |||
*Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with non-life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs. | |||
</b> | |||
|} | |||
</font> | |||
==Taking Alcohol with Propafenone== | |||
Alcohol-Propafenone interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antiarrhythmic agents]] | |||
[[Category:Ketones]] | |||
[[Category:Phenol ethers]] | |||
[[Category:Alcohols]] | |||
[[Category:Amines]] | |||
[[Category:Sodium channel blockers]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] | |||
Revision as of 03:00, 12 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Propafenone, click here.
Synonyms / Brand Names: RYTHMOL®;RYTHMOL SR®;generic
Overview
Category
;Ketones;Phenol ethers;Alcohols;Amines;Sodium channel blockers;Cardiovascular Drugs
FDA Package Insert
RYTHMOL (propafenone hydrochloride) tablet, film coated
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
|
BOXED WARNING See full prescribing information for complete boxed warning.
WARNING: MORTALITY See full prescribing information for complete boxed warning. An increased rate of death or reversed cardiac arrest rate was seen in subjects treated with encainide or flecainide (Class IC antiarrhythmics) compared with that seen in subjects assigned to placebo. At present it is prudent to consider any IC antiarrhythmic to have a significant risk of provoking proarrhythmic events in patients with structural heart disease. Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with non-life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.
|
RYTHMOL SR (propafenone hydrochloride) capsule, extended release
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
|
BOXED WARNING See full prescribing information for complete boxed warning.
WARNING: MORTALITY See full prescribing information for complete boxed warning.
|
Taking Alcohol with Propafenone
Alcohol-Propafenone interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.